Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

NCT03009058 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Commercial reasons

Conditions

Metastatic Cancer

Interventions

BIOLOGICAL: IMM-101
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: Capecitabine
DRUG: Folinic Acid
DRUG: Fluorouracil
DRUG: Irinotecan
DRUG: Oxaliplatin
BIOLOGICAL: cetuximab
BIOLOGICAL: Anti-PD1
BIOLOGICAL: Ipilimumab
DRUG: Cyclophosphamide

Sponsor

Immodulon Therapeutics Ltd